Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDcalm is a plant-based dietary supplement developed by MDbio Wellness, specifically formulated to address stress and promote relaxation. Its composition features a synergistic blend of hemp-derived phytocannabinoids, including cannabidiol (CBD) and cannabigerol (CBG), alongside botanical adaptogens and amino acids such as Ashwagandha, L-Theanine, and GABA. The product was evaluated in a large-scale, blinded, placebo-controlled virtual clinical trial conducted by Radicle Science to provide scientific validation of its efficacy in reducing stress and anxiety in real-world populations. MDcalm is designed to modulate the body's stress response by interacting with the endocannabinoid system and the hypothalamic-pituitary-adrenal (HPA) axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MDcalm.